Aldevron Names Michelle Berg President of GMP Business Unit
Aldevron has expanded its leadership team by appointing Michelle Berg President of its GMP nucleic acids business unit. She will report to Michael Chambers, Aldevron’s founder and CEO.
Aldevron Announces 1,000 Liter Fermentation Capacity and Significant Manufacturing Space Expansion
Aldevron announced today its new fermentation capacity of 1,000 liters and plans to significantly increase the Company’s manufacturing footprint in Madison, WI. The large-scale fermentation equipment is already installed and will be coming on-line in Q4 2019.
Aldevron Names Michael Jablon as Senior Director of Information Systems
Michael Jablon of Aldevron has been named Senior Director of Information Systems. In this position, Jablon will lead Information Systems initiatives to improve efficiency, streamline operations, optimize information security and design innovative systems that will enable Aldevron’s clients to more rapidly advance treatments and gene therapies for their patients.
Aldevron Releases GMP-Grade SpyFi™ Cas9 Nuclease
Product is the result of a partnership with Integrated DNA Technologies, Inc., and provides clinical stage clients with a critical raw material
Aldevron is announcing the release of GMP SpyFi Cas9 Nuclease for clinical and commercial applications. SpyFi Cas9 Nuclease, the trade name for Aldevron’s research grade and GMP products, is the direct result of a partnership with Integrated DNA Technologies, Inc. (IDT). The advantages of SpyFi Cas9 Nuclease include reduced off-target effects combined with clinically relevant on-target activity.
Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron
Agreement provides Sarepta with committed capacity and dedicated manufacturing slots for GMP-grade plasmid production for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program, as well as plasmid capacity for future gene therapy programs
Cambridge, Mass., January 2, 2019 - Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases and Aldevron, the leading producer of custom nucleic acids, proteins, and antibodies for the biotechnology industry, announced today that they have entered into a long-term strategic relationship for the supply of plasmid DNA to fulfill Sarepta’s needs for its gene therapy clinical trials and commercial supply.
Aldevron Names Mike Busch Vice President of Human Resources
Aldevron has expanded its leadership team by appointing Mike Busch as Vice President of Human Resources.